Clinical Efficacy, Tolerability and Safety of a New Multiple-Action Eyedrop in Subjects with Moderate to Severe Dry Eye

Background: To assess the clinical efficacy, tolerability and safety of a new-generation ophthalmic solution containing cross-linked hyaluronic acid 0.15% trehalose 3%, liposomes 1% and sterylamine 0.25% (Trimix(®) Off Health Italia, Firenze, Italy) (CXHAL) versus trehalose 3% (Thealoz(®), Thea Phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Roszkowska, Anna Maria, Inferrera, Leandro, Spinella, Rosaria, Postorino, Elisa Imelde, Gargano, Romana, Oliverio, Giovanni Wiliam, Aragona, Pasquale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740530/
https://www.ncbi.nlm.nih.gov/pubmed/36498550
http://dx.doi.org/10.3390/jcm11236975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740530/
https://www.ncbi.nlm.nih.gov/pubmed/36498550
http://dx.doi.org/10.3390/jcm11236975

Ejemplares similares